Professor of Medicine, Dana-Farber Cancer Institute
Hematology
Dr. Margaret A. Shipp, MD
|
|
Give Review
Margaret Shipp practices Hematology. She studied medicine at Washington University School of Medicine in St. Louis. She over the years received 2 awards: "Elected Member" and "Super Doctor". Margaret Shipp is a published physician. She published 101 publications, including: 'The cellular and molecular heterogeneity of the aggressive non-Hodgkin's lymphomas.'
Publications
- Genetic Basis for PD-L1 Expression in Squamous Cell Carcinomas of the Cervix and Vulva.
- Molecular Classification of MYC-Driven B-Cell Lymphomas by Targeted Gene Expression Profiling of Fixed Biopsy Specimens.
- PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma.
- Glycosylation-Dependent Lectin-Receptor Interactions Preserve Angiogenesis in Anti-VEGF Refractory Tumors.
- Discovery and characterization of super-enhancer-associated dependencies in diffuse large B cell Lymphoma.
- PD-L1 Expression Is Characteristic of a Subset of Aggressive B-cell Lymphomas and Virus-Associated Malignancies.
- Galectin-1 serum levels reflect tumor burden and adverse clinical features in classical Hodgkin Lymphoma.
- BAL1 and Its Partner E3 Ligase, BBAP, Link Poly(ADP-Ribose) Activation, Ubiquitylation, and Double-Strand DNA Repair Independent of ATM, MDC1, and RNF8.
- A unique galectin signature in human prostate cancer progression suggests galectin-1 as a key target for treatment of advanced Disease.
- Integrative Analysis Reveals an Outcome-Associated and Targetable Pattern of p53 and Cell Cycle Deregulation in Diffuse Large B Cell Lymphoma.
- Aberrant Expression of the Dendritic Cell Marker TNFAIP2 by the Malignant Cells of Hodgkin Lymphoma and Primary Mediastinal Large B-Cell Lymphoma Distinguishes These T...
- Viral induction and targeted inhibition of galectin-1 in EBV+ posttransplant lymphoproliferative Disorders.
- Signatures of murine B-cell development implicate Yy1 as a regulator of the germinal center-specific program.
- Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin Lymphoma an...
- MLL-rearranged B lymphoblastic Leukemias selectively express the immunoregulatory carbohydrate-binding protein galectin-1.
- Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic Leukemia.
- BCL6 modulates tonic BCR signaling in diffuse large B-cell Lymphomas by repressing the SYK phosphatase, PTPROt.
- BBAP monoubiquitylates histone H4 at lysine 91 and selectively modulates the DNA damage response.
- AP1-dependent galectin-1 expression delineates classical hodgkin and anaplastic large cell Lymphomas from other lymphoid malignancies with shared molecular features.
- SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell Lymphoma.
- BCL6 programs Lymphoma cells for survival and differentiation through distinct biochemical mechanisms.
- The AP1-dependent secretion of galectin-1 by Reed Sternberg cells fosters immune privilege in classical Hodgkin Lymphoma.
- Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell Lymphoma.
- Molecular signatures define new rational treatment targets in large B-cell Lymphomas.
- Expression of TRAF1 and nuclear c-Rel distinguishes primary mediastinal large cell Lymphoma from other types of diffuse large B-cell Lymphoma.
- Heterogeneous CD52 expression among hematologic neoplasms: implications for the use of alemtuzumab (CAMPATH-1H).
- Protein tyrosine phosphatase receptor-type O truncated (PTPROt) regulates SYK phosphorylation, proximal B-cell-receptor signaling, and cellular proliferation.
- BAL1 and BBAP are regulated by a gamma interferon-responsive bidirectional promoter and are overexpressed in diffuse large B-cell Lymphomas with a prominent inflammato...
- FAS death domain deletions and cellular FADD-like interleukin 1beta converting enzyme inhibitory protein (long) overexpression: alternative mechanisms for deregulating...
- Inactivation of the PRDM1/BLIMP1 gene in diffuse large B cell Lymphoma.
- Lack of IKBA coding region mutations in primary mediastinal large B-cell lymphoma and the Host response subtype of diffuse large B-cell lymphoma.
- B-aggressive Lymphoma family proteins have unique domains that modulate transcription and exhibit poly(ADP-ribose) polymerase activity.
- NFkappaB activity, function, and target-gene signatures in primary mediastinal large B-cell Lymphoma and diffuse large B-cell Lymphoma subtypes.
- Advances in the biology and therapy of diffuse large B-cell Lymphoma: moving toward a molecularly targeted approach.
- Case records of the Massachusetts General Hospital. Case 12-2005. A 30-year-old woman with a mediastinal mass.
- Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by Host inflammatory response.
- TRAF1 expression and c-Rel activation are useful adjuncts in distinguishing classical Hodgkin Lymphoma from a subset of morphologically or immunophenotypically similar...
- Tumor cell-mediated induction of the stromal factor stromelysin-3 requires heterotypic cell contact-dependent activation of specific protein kinase C isoforms.
- The phosphodiesterase PDE4B limits cAMP-associated PI3K/AKT-dependent apoptosis in diffuse large B-cell Lymphoma.
- Cloning of the t(1;5)(q23;q33) in a Myeloproliferative disorder associated with eosinophilia: involvement of PDGFRB and response to imatinib.
- The molecular signature of mediastinal large B-cell Lymphoma differs from that of other diffuse large B-cell Lymphomas and shares features with classical Hodgkin lymph...
- The BAL-binding protein BBAP and related Deltex family members exhibit ubiquitin-protein isopeptide ligase activity.
- Molecular diagnostics.
- Rituximab and CHOP induction therapy for newly diagnosed mantle-cell Lymphoma: molecular complete responses are not predictive of progression-free survival.
- Diffuse large B-cell Lymphoma outcome prediction by gene-expression profiling and supervised machine learning.
- The pre-B-cell receptor associated protein VpreB3 is a useful diagnostic marker for identifying c-MYC translocated Lymphomas.
- The heat shock protein 90 inhibitor IPI-504 induces apoptosis of AKT-dependent diffuse large B-cell Lymphomas.
- High dose CHOP: a phase II study of initial treatment in aggressive non-Hodgkin lymphoma. Cancer and Leukemia Group B 9351.
- Seventy-two hour continuous infusion flavopiridol in relapsed and refractory mantle cell Lymphoma.
- Expression of bcl-6 and CD10 in primary mediastinal large B-cell Lymphoma: evidence for derivation from germinal center B cells?
- BAL is a novel risk-related gene in diffuse large B-cell Lymphomas that enhances cellular migration.
- High-dose CHOP as initial therapy for patients with poor-prognosis aggressive non-Hodgkin's Lymphoma: a dose-finding pilot study.
- Early restaging gallium scans predict outcome in poor-prognosis patients with aggressive non-Hodgkin's Lymphoma treated with high-dose CHOP chemotherapy.
- Stromelysin-3 is induced in tumor/stroma cocultures and inactivated via a tumor-specific and basic fibroblast growth factor-dependent mechanism.
- PTPROt: an alternatively spliced and developmentally regulated B-lymphoid phosphatase that promotes G0/G1 arrest.
- The m-BACOD combination chemotherapy regimen in large-cell Lymphoma: analysis of the completed trial and comparison with the M-BACOD regimen.
- Value of follow-up procedures in patients with large-cell Lymphoma who achieve a complete remission.
- Patterns of relapse in large-cell lymphoma patients with bulk Disease: implications for the use of adjuvant radiation therapy.
- Transcriptional signature with differential expression of BCL6 target genes accurately identifies BCL6-dependent diffuse large B cell Lymphomas.
- Large-cell and immunoblastic Lymphoma of the mediastinum: prognostic features and treatment outcome in 57 patients.
- Alternatively spliced CD44 transcripts in diffuse large-cell Lymphomas: characterization and comparison with normal activated B cells and epithelial malignancies.
- International Consensus Conference on High-Dose Therapy with Hematopoietic Stem Cell Transplantation in Aggressive Non-Hodgkin's Lymphomas: report of the jury.
- The type 2 CD10/neutral endopeptidase 24.11 promoter: functional characterization and tissue-specific regulation by CBF/NF-Y isoforms.
- CD10/NEP is expressed on Thy-1low B220+ murine B-cell progenitors and functions to regulate stromal cell-dependent lymphopoiesis.
- Identification of a second transforming gene, rasn, in a human multiple Myeloma line with a rearranged c-myc allele.
- Molecular cloning of the common Acute lymphoblastic leukemia antigen (CALLA) identifies a type II integral membrane protein.
- Drug-related pulmonary toxicity in non-Hodgkin's Lymphoma. Comparative results with three different treatment regimens.
- Modified magrath regimens for adults with Burkitt and Burkitt-like Lymphomas: preserved efficacy with decreased toxicity.
- Active stromelysin-3 (MMP-11) increases MCF-7 survival in three-dimensional Matrigel culture via activation of p42/p44 MAP-kinase.
- Integrative analysis reveals 53BP1 copy loss and decreased expression in a subset of human diffuse large B-cell Lymphomas.
- Stromelysin-3 suppresses tumor cell apoptosis in a murine model.
- No evidence for the JAK2 (V617F) or JAK2 exon 12 mutations in primary mediastinal large B-cell Lymphoma.
- Prognostic factors in aggressive non-Hodgkin's lymphoma: who has "high-risk" Disease?
- International Consensus Conference on high-dose therapy with hematopoietic stem-cell transplantation in aggressive non-Hodgkin's Lymphomas: report of the jury.
- BH3 profiling identifies three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agents.
- A directly spliced exon 10-containing CD44 variant promotes the metastasis and homotypic aggregation of aggressive non-Hodgkin's Lymphoma.
- Phase I trial of the matrix metalloproteinase inhibitor marimastat combined with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer.
- Inhibition of CD10/neutral endopeptidase 24.11 promotes B-cell reconstitution and maturation in vivo.
- GLEPP1/protein-tyrosine phosphatase phi inhibitors block chemotaxis in vitro and in vivo and improve murine ulcerative colitis.
- The cellular and molecular heterogeneity of the aggressive non-Hodgkin's Lymphomas.
- The m-BACOD combination chemotherapy regimen in the treatment of diffuse large cell Lymphoma.
- Identification of major prognostic subgroups of patients with large-cell Lymphoma treated with m-BACOD or M-BACOD.
- The angiogenic factor interleukin 8 is induced in non-small cell lung cancer/pulmonary fibroblast cocultures.
- FBXO11 targets BCL6 for degradation and is inactivated in diffuse large B-cell Lymphomas.
- CD10/neutral endopeptidase 24.11 is phosphorylated by casein kinase II and coassociates with other phosphoproteins including the lyn src-related kinase.
- New concepts in treatment approaches and prognostic factors in aggressive NHL.
- Stromelysin-3 is overexpressed by stromal elements in primary non-small cell lung cancers and regulated by retinoic acid in pulmonary fibroblasts.
- Chemotherapy of non-Hodgkin's aggressive Lymphomas.
- Report of an international workshop to standardize response criteria for non-Hodgkin's Lymphomas. NCI Sponsored International Working Group.
- Analysis of the human CD10/neutral endopeptidase 24.11 promoter region: two separate regulatory elements.
- CD10 (CALLA)/neutral endopeptidase 24.11 modulates inflammatory peptide-induced changes in neutrophil morphology, migration, and adhesion proteins and is itself regula...
- Phorbol ester-mediated regulation of CD10/neutral endopeptidase transcripts in Acute lymphoblastic leukemias.
- Opioid receptor agonists and Ca2+ modulation in human B cell lines.
- Four patients with myelodysplastic syndrome with translocation (1;7)(p11;p11) including one patient with independent clones del(7)q22) [corrected] and t(1;7)(q21;q11)
- CD10/neutral endopeptidase 24.11 hydrolyzes bombesin-like peptides and regulates the growth of small cell carcinomas of the lung.
- Common Acute lymphoblastic leukemia antigen (CALLA) is active neutral endopeptidase 24.11 ("enkephalinase"): direct evidence by cDNA transfection analysis.
- Organization of the gene encoding common Acute lymphoblastic leukemia antigen (neutral endopeptidase 24.11): multiple miniexons and separate 5' untranslated regions.
- CD10/neutral endopeptidase 24.11 in developing human fetal lung. Patterns of expression and modulation of peptide-mediated proliferation.
- Murine common Acute lymphoblastic leukemia antigen (CD10 neutral endopeptidase 24.11). Molecular characterization, chromosomal localization, and modeling of the active...
- High-dose cytosine arabinoside. Active agent in treatment of non-Hodgkin's Lymphoma.
Schools
Washington University St Louis
Barnes HospWashington Univmo
Dana FarberHarvard Med School
Procedures Preformed
- HPC Transplantation (Stem Cell Transplant)
Conditions Treated
- Acute Leukemia
- Anemia
- Graft vs Host Disease
- Hodgkin's Disease
- View All
Doctors Specialties
- Medical Oncology
- Oncology
- Hematology
Accepted Insurances
Awards
- Elected Member
- Super Doctor
Education
-
Washington University - Barnes-Jewish Hospital -
Washington University School of Medicine in St. Louis
Hospital
-
Brigham and Women's Hospital -
Massachusetts General Hospital -
Dana-Farber Cancer Institute
Helpful Reviews
Similar Doctors
|
|
Dr. Stefanie Sarantopoulos, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Judy E. Garber, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. David A. Frank, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Catherine J. Wu, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Corey S. Cutler, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Kala Seetharaman, MB
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Robert I. Haddad, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Paul G. Richardson, MD |
|
|
Dr. Rasmia A. Khalid, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Steven P. Treon, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Richard M. Stone, MD |
|
|
Dr. Joseph H. Antin, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Daniel J. Deangelo, MD
This Doctor is OpenDoctor Recommended.
|